

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Lindor, Keith D.	POSITION TITLE		
eRA COMMONS USER NAME KEITHLINDOR	Dean, Mayo Medical School		
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
University of Minnesota, Minneapolis, MN	B.S.	1971-1975	Chemistry
Mayo Medical School, Rochester, MN	M.D.	1975-1979	Medicine
Wake Forest University, Winston-Salem, NC		1979-1982	Internal Medicine
Mayo Clinic, Rochester MN		1983-1986	Gastroenterology

A. Positions and Honors

1982-1983	General Medical Officer, Indian Health Service, Sells, AZ
1986-Present	Consultant in Gastroenterology, Mayo Clinic, Rochester, MN
1989-1994	Gastroenterology Training Program Director, Mayo Clinic, Rochester, MN
1994-1999	Chair for Practice in Gastroenterology, Mayo Clinic, Rochester, MN
1999-2005	Chair, Division of Gastroenterology, Mayo Clinic, Rochester, MN
2005	Dean Mayo Medical School
2007	Editor-in-Chief, HEPATOLOGY

B. Selected peer-reviewed publications

1. Charatchoenwittaya P, Lindor KD. Current concepts in the pathogenesis of primary biliary cirrhosis. *Ann Hepatol* 2005;4(3):161-75.
2. Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. *Liver Int* 2005 Aug; 25(4):779-86.
3. Levy C, Lymp J, Angulo P, Gores GJ, Larusso N, Lindor KD. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. *Dig Dis Sci* 2005 Sep; 50(9):1734-40.
4. Zein CO, Jorgensen RA, Clarke B, Wenger DE, Keach JC, Angulo P, Lindor KD. Alendronate improves bone mineral density in primary biliary cirrhosis: A randomized placebo-controlled trial. *Hepatology* 2005 Oct; 42(4):762-71.
5. Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, Lindor KD, Kaplan MM, Vierling JM. Risk factors and comorbidities in primary biliary cirrhosis: A controlled interview-based study of 1032 patients. *Hepatology* 2005 Nov; 42(5):1194-202.
6. Suzuki A, Lindor K, St Saver J, Lymp J, Mendes F, Muto A, Okada T, Angulo P. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. *J Hepatol* 2005 Dec;43(6):1060-6
7. Levy C, Lindor K. Primary sclerosing cholangitis: epidemiology, natural history, and prognosis. *Semin Liver Dis* 2006 Feb;26(1):22-30.
8. Charatchoenwittaya P, Lindor K. Primary sclerosing cholangitis: diagnosis and management. *Curr Gastroenterol Rep* 2006 Feb;8(1):75-82.
9. Mendes FD, Jorgensen R, Keach J, Katzmann JA, Smyrk T, Donlinger J, Chari S, Lindor KD. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. *Am J Gastroenterol* 2006;101(9):2070-5.
10. Talwalkar JA, Donlinger JJ, Gossard AA, Keach JC, Jorgensen RA, Petz JC, Lindor KD. Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial. *Dig Dis Sci* 2006;51(11):1985-91.

11. Mendes FD, Levy C, Enders FB, Loftus EV, Angulo P, Lindor KD. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. *Am J Gastroenterol* 2007;102(2):344-50.
12. Suzuki A, Lymp J, St. Sauver J, Angulo P, Lindor K. Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. *Liver Int* 2006;26(10):1209-16.
13. Lazaridis K, Lindor KD. Management of primary biliary cirrhosis: From diagnosis to end-stage disease. *Current Gastroenterology Reports* 2007; 2(2):94-98.
14. Charatchoenwittaya P, Lindor KD. Primary sclerosing cholangitis: patients with a rising alkaline phosphatase at annual follow-up. *Clin Gastroenterol Hepatol* 2007;5(1):32-6.
15. Mendes FD, Levy C, Enders FB, Loftus EV, Angulo P, Lindor KD. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. *Am J Gastroenterol* 2007;102(2):344-50.
16. Suzuki A, Lymp J, Donlinger J, Mendes F, Angulo P, Lindor K. Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis. *Clin Gastroenterol Hepatol* 2007;5(2):259-64.
17. Charatchoenwittaya P, Levy C, Angulo P, Keach J, Jorgensen R, Lindor KD. Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis. *Liver Int* 2007;27(2):220-6.
18. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. *Hepatology* 2007;45(4):846-54.
19. Talwalkar JA, Gossard AA, Keach JC, Jorgensen RA, Petz JL, Lindor RNKD. Tacrolimus for the treatment of primary sclerosing cholangitis. *Liver Int* 2007;27(4):451-3.
20. Lindor KD. Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis. *Liv Int*. 2007;27(2):220-6.
21. Silveira MG, Talwalkar JA, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. *Am J Gastroenterol* 2007;102(6):1244-50.
22. Charatchoenwittaya P, Lindor KD. Role of radiologic modalities in the management of non-alcoholic steatohepatitis. *Clin Liver Dis* 2007;11(1):37-54.
23. Panjala C, Talwalkar JA, Lindor KD. Risk of lymphoma in primary biliary cirrhosis. *Clin Gastroenterol Hepatol* 2007;5(6):761-4.
24. Lazaridis KN, Juran BD, Boe GM, Slusser JP, de Andrade M, Homburger HA, Chosh K, Dickson ER, Lindor KD, Petersen GM. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. *Hepatology* 2007;46(3):785-92.
25. Nelson JE, Bhattacharya R, Lindor KD, Chalasani N, Raaka S, Heathcote EJ, Miskovsky E, Shaffer E, Rulyak SJ, Kowdley KV. *Hepatology* 2007;46(3):723-9.
26. Steele IL, Levy C, Lindor KD. Primary sclerosing cholangitis – approach to diagnosis. *Med Gen Med* 2007;25;9(2):20.
27. Charatchoenwittaya P, Pimentel S, Talwalkar JA, Enders FT, Lindor KD, Krom RA, Wiesner RH. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. *Liver Transpl* 2007;13(9):1236-1245.
28. Bjornsson E, Chari ST, Smyrk TC, Lindor K. Immunoglobulin G4 associated cholangitis: description of an emerging clinic entity based on review of the literature. *Hepatology* 2007;45(6):1547-54.
29. Suzuki An, Angulo P, St. Sauver J, Muto A, Okada T, Lindor K. Light to moderate alcohol consumption is associated with lower frequency of hypertransaminasemia. *Am J Gastroenterol* 2007;102(9):1912-9.
30. Gossard AA, Lindor KD. Development of autoimmune hepatitis in primary biliary cirrhosis. *Liver Int* 2007;27(8):1086-90.
31. Lindor KD. Characteristics of primary sclerosing cholangitis in the USA. *Hepatol Res* 2007;37 Suppl 3:S474-7.
32. Angulo P, Jorgensen RA, Kowdley KV, Lindor KD. Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study. *Dig Dis Sci* 2007 [Epub ahead of print].
33. Lindor K. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. *N Engl J Med* 2007;357(15):1524-9.
34. Viggiano TR, Pawlina W, Lindor KD, Olsen KD, Cortese DA. Putting the needs of the patient first: Mayo clinic's core value, institutional culture, and professionalism covenant. *Acad Med* 2007;82(11):1089-93.
35. Charatchoenwittaya P, Angulo P, Enders FB, Lindor KD. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis. *Hepatology* 2007 [Epub ahead of print].
36. Adams LA, Lindor KD. Nonalcoholic fatty liver disease. *Ann Epidemiol* 2007;17(11):863-9.

C. Research Support

Ongoing Research Support

R01 DK56924 Lindor (PI) 12/01/99-7/31/12

NIH

Multicentered Randomized Trial of High Dose Urso in PSC

The major goals of this project are to assess the efficacy of high dose UDCA in PSC patients.

Role: PI

Completed Research Support

INDUSORPHAN #2 Lindor (PI) 12/15/02-12/14/04

Orphan Medical

A randomized, placebo-controlled trial of Betaine in patients with NASH

The major goal of this study is to evaluate the value of Betaine as treatment in NASH.

Role: PI

INDUSWAKO #1, 1A4813-1 Lindor (PI) 03/01/03-02/29/04

Wako

Markers of Fibrosis in Non-Alcoholic Steatohepatitis

The major goal of the study is to determine the value of a new marker in predicting fibrosis in NASH.

Role: PI